| OALBA0102 | Immune correlates analysis of the Imbokodo HIV-1 vaccine efficacy trial | Oral abstract session with live Q&A | Humoral immunity (including broadly neutralizing antibodies), Antibodies and B cells |
| OALBA0103 | Flt3 agonist enhances immunogenicity of arenavirus-vector based vaccines in macaques | Oral abstract session with live Q&A | Novel vectors, adjuvants and strategies |
| OALBA0105 | Metabolomic and lipidomic correlates of time-to-HIV-rebound in viremic controllers treated with vesatolimod | Oral abstract session with live Q&A | Correlates of HIV susceptibility, and progression versus control (biomarkers and genetics) |
| OALBB0102 | Phase I/II study of monoclonal antibody VRC01 with early antiretroviral therapy to promote clearance of HIV-1 infected cells in infants (IMPAACT 2008) | Oral abstract session with live Q&A | Cure strategies in paediatric and adolescent populations |
| OALBB0103 | Enhanced tuberculosis screening using computer-aided X-ray diagnosis and novel point of care urine lipoarabinomannan assay among adults with HIV admitted to hospital (CASTLE study): a cluster randomised trial | Oral abstract session with live Q&A | Tuberculosis: Prevention, diagnosis, treatment |
| OALBB0104 | The 'City of Hope' Patient: prolonged HIV-1 remission without antiretrovirals (ART) after allogeneic hematopoietic stem cell transplantation (aHCT) of CCR5-Î?32/Î?32 donor cells for acute myelogenous leukemia (AML) | Oral abstract session with live Q&A | Cure interventions |
| OALBB0105 | Incident tuberculosis as a risk factor for viral non-suppression 48 weeks among patients switched to dolutegravir based therapy with recycled nucleoside reverse transcriptase inhibitors in Lusaka, Zambia | Oral abstract session with live Q&A | Viral load and CD4 monitoring |
| OALBC0102 | High prevalence of asymptomatic Omicron carriage and correlation with CD4+ T cell count among adults with HIV enrolling in COVPN 3008 Ubuntu clinical trial in sub-Saharan Africa | Oral abstract session with live Q&A | Epidemiology of COVID-19 among persons living with HIV and / or including tuberculosis |
| OALBC0103 | A phase IV open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1 | Oral abstract session with live Q&A | Demonstration and pilot projects for prevention (including PrEP, PEP, male circumcision) |
| OALBC0104 | National roll out of community HIV screening among key populations in Indonesia: assessment of early results | Oral abstract session with live Q&A | HIV self-testing |